AMICUS THERAPEUTICS,INC. (NASDAQ:FOLD) Files An 8-K Other Events
Item8.01. Other Events.
On April3, 2017, Amicus Therapeutics,Inc. (the Company) issued a
press release announcing the completion of enrollment of the
Companys ESSENCE Phase 3 Epidermolysis Bullosa Clinical Study. A
copy of this press release is attached hereto as Exhibit99.1.
The Company also provided a summary of its Epidermolysis Bullosa
program of which a copy is attached hereto as Exhibit99.2.
Item 9.01. Financial Statements and Exhibits.
(d)Exhibits: The ExhibitIndex annexed hereto is incorporated
herein by reference.
|
Exhibit No. |
|
Description |
|
99.1 |
Press Release dated April3, 2017 titled Amicus Therapeutics |
|
|
99.2 |
Presentation Materials Epidermolysis Bullosa Program |
About AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD)
Amicus Therapeutics, Inc. is a biotechnology company. The Company is engaged in the discovery, development and commercialization of a set of treatments for patients living with devastating rare and orphan diseases. Its lead product, migalastat HCl is a small molecule that can be used as a monotherapy and in combination with enzyme replacement therapy (ERT) for Fabry disease. Its pipeline also includes SD-101, which is a product candidate in late-stage development, as a potential first-to-market therapy for the chronic, rare connective tissue disorder Epidermolysis Bullosa (EB). It is also leveraging its Chaperone-Advanced Replacement Therapy (CHART) platform technologies to develop ERT products for Pompe disease, Fabry disease, and potentially other lysosomal storage disorders (LSDs). The Company is also investigating preclinical and discovery programs in other rare and devastating diseases, including cyclin-dependent kinase-like 5 (CDKL5) deficiency. AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) Recent Trading Information
AMICUS THERAPEUTICS, INC. (NASDAQ:FOLD) closed its last trading session 00.00 at 7.13 with 2,125,810 shares trading hands.